Mitsubishi UFJ Asset Management Co. Ltd. Purchases 18,008 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 14.9% during the fourth quarter, HoldingsChannel reports. The fund owned 138,795 shares of the biopharmaceutical company’s stock after buying an additional 18,008 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $55,542,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Mediolanum International Funds Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at about $11,389,000. Rakuten Investment Management Inc. bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth approximately $14,205,000. Cerity Partners LLC increased its position in shares of Alnylam Pharmaceuticals by 171.2% in the third quarter. Cerity Partners LLC now owns 27,429 shares of the biopharmaceutical company’s stock worth $12,507,000 after purchasing an additional 17,316 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth approximately $5,790,000. Finally, Perpetual Ltd bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth approximately $2,004,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Down 0.3%

Shares of ALNY opened at $295.05 on Friday. The firm has a market cap of $39.39 billion, a P/E ratio of 80.61 and a beta of 0.31. The stock has a 50 day simple moving average of $318.15 and a two-hundred day simple moving average of $372.43. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. Alnylam Pharmaceuticals, Inc. has a 1 year low of $250.35 and a 1 year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $1.12. The business had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.Alnylam Pharmaceuticals’s revenue for the quarter was up 96.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.44) earnings per share. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,598 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $523,584.70. Following the completion of the sale, the executive vice president owned 36,606 shares of the company’s stock, valued at $11,993,955.90. This represents a 4.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jeffrey V. Poulton sold 2,206 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $722,795.90. Following the completion of the sale, the executive vice president directly owned 64,273 shares of the company’s stock, valued at approximately $21,059,048.45. This represents a 3.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 38,656 shares of company stock valued at $12,370,696 over the last 90 days. Company insiders own 0.86% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on ALNY shares. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday. Raymond James Financial restated an “outperform” rating and issued a $472.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. Truist Financial decreased their price objective on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a research report on Monday, April 13th. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, Bank of America restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $471.96.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to $7.86 from $7.31, suggesting stronger near-term profitability expectations for Alnylam.
• Positive Sentiment: The same analyst kept a Buy rating and reiterated a $510 price target, signaling continued confidence in Alnylam’s longer-term growth outlook.
• Positive Sentiment: HC Wainwright also lifted its Q2 2026 EPS estimate to $1.43 from $1.36, which is a modest short-term improvement.
• Neutral Sentiment: Several longer-dated earnings forecasts were mostly trimmed only slightly, including FY2027, FY2028, FY2029, and FY2030, which suggests only minor adjustments rather than a major change in the investment thesis.
• Negative Sentiment: HC Wainwright lowered its Q3 2026 and Q4 2026 EPS estimates, which may have tempered enthusiasm around the company’s earnings trajectory.
• Negative Sentiment: An FDA untitled letter regarding Amvuttra survival claims may have added regulatory uncertainty and weighed on sentiment toward ALNY. FDA’s Untitled Letter tells Alnylam its Amvuttra survival claims don’t quite add up

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.